Non Small Cell Lung Cancer Clinical Trial
Official title:
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
Verified date | February 2012 |
Source | AEterna Zentaris |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a study of the drug perifosine that consists of 2 parts. The first part of this study
was designed to determine the highest dose of perifosine that can be administered to people
every week without severe or prolonged nausea, vomiting and diarrhea. This study started with
patients taking 900 mg/week and went up to 1800 mg/week. Part I of this study is completed.
The MTD had been determined and incorporated in Part II.
The goals in Part II are to:
1. Compare the gastrointestinal toxicity of 3 different dose-schedules and
2. Obtain preliminary information on the response rate of perifosine in non-small cell lung
cancer.
Status | Completed |
Enrollment | 121 |
Est. completion date | December 2011 |
Est. primary completion date | December 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients must have histologically or cytologically confirmed diagnosis of non-small cell lung cancer, must have progressed despite standard therapy and must not be candidates for surgical or combined modality therapy. - At least 18 years of age. - Patients should have received at least one but no more than two prior chemotherapy regimens for metastatic disease. The study chairman or medical monitor will consider extenuating circumstances for patients with more than two such regimens. - Patients must have measurable disease. Since the outcome for a patient is to be based on response using RECIST criteria, the patient must have at least one measurable lesion that can be accurately measured in at least one dimension and fit one of the following criteria: longest diameter 20 mm using conventional techniques or 10 mm with spiral CT scan. - Patients must have a life expectancy of more than 3 months. - Patients should have a performance status of 0 to 1 according to the ECOG criteria. However, patients with ECOG performance status of 2 may be admitted with approval from the study chairman or medical monitor. - Female patients who are pregnant or lactating are ineligible. All females of childbearing potential must have a negative serum pregnancy test within 72 hours of treatment. Men and women of childbearing potential must agree to employ adequate contraception to prevent pregnancy while on therapy and for four weeks after the completion of treatment. - Patients must have ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria - Patients with rapidly progressing disease, as defined by progression within 12 weeks of initiation of the previous regimen. - Patients receiving any other investigational agents or devices. - History of allergic reactions attributed to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine). - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection and psychiatric illness/social situations that would limit compliance with study requirements. - HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with perifosine. - Patients with a history of unstable or newly diagnosed angina pectoris, recent myocardial infarction (within 6 months of enrollment) or New York Heart Assoc. class II-IV congestive heart failure. |
Country | Name | City | State |
---|---|---|---|
United States | AOI Pharmaceuticals Investigative Site | Albany | New York |
United States | AOI Pharmaceuticals Investigative Site | Albuquerque | New Mexico |
United States | AOI Pharmaceuticals Investigative Site | Armonk | New York |
United States | AOI Pharmaceuticals Investigative Site | Aventura | Florida |
United States | AOI Pharmaceuticals Investigative Site | Billings | Montana |
United States | AOI Pharmaceuticals Investigative Site | Chattanooga | Tennessee |
United States | AOI Pharmaceuticals Investigative Site | Dallas | Texas |
United States | AOI Pharmaceuticals Investigative Site | Dallas | Texas |
United States | AOI Pharmaceuticals Investigative Site | Galesburg | Illinois |
United States | AOI Pharmaceuticals Investigative Site | Grand Rapids | Michigan |
United States | AOI Pharmaceuticals Investigative Site | Greenville | South Carolina |
United States | AOI Pharmaceuticals Investigative Site | Hollywood | Florida |
United States | AOI Pharmaceuticals Investigative Site | Kalamazoo | Michigan |
United States | AOI Pharmaceuticals Investigative Site | Lakeland | Florida |
United States | AOI Pharmaceuticals Investigative Site | Lawrenceville | Georgia |
United States | AOI Pharmaceuticals Investigative Site | Nashville | Tennessee |
United States | AOI Pharmaceuticals Investigative Site | New Albany | Indiana |
United States | AOI Pharmaceuticals Investigative Site | Ormond Beach | Florida |
United States | AOI Pharmaceuticals Investigative Site | Pomona | California |
United States | AOI Pharmaceuticals Investigative Site | Tucson | Arizona |
United States | AOI Pharmaceuticals Investigative Site | Tyler | Texas |
Lead Sponsor | Collaborator |
---|---|
AEterna Zentaris |
United States,
Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 24, No 18S (June 20 Supplement), 2006: 13063
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Gastrointestinal toxicity of 3 different dose-schedules | The frequency of grade 2 or greater gastrointestinal toxicities between the 3 arms of the study will be observed and used to determine the best regimen | 12 weeks | |
Secondary | Preliminary information on response rate | To test if the response rate of perifosine in non small cell lung cancer is > 10% in any of the 3 arms of the study. | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Completed |
NCT01945021 -
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
|
Phase 2 | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
Recruiting |
NCT05898763 -
TEIPP Immunotherapy in Patients With NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05532696 -
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04311034 -
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00349089 -
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
|
Phase 2 | |
Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04571632 -
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
|
Phase 2 | |
Terminated |
NCT03599518 -
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06020989 -
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
|
Phase 2 | |
Withdrawn |
NCT03982134 -
PDR001 + Panobinostat for Melanoma and NSCLC
|
Phase 1 | |
Withdrawn |
NCT03574649 -
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT02844140 -
DE-CT in Lung Cancer Proton Therapy
|
N/A | |
Completed |
NCT03780010 -
Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC
|
Phase 1 |